A Novel Small-Molecule Integrin Antagonist Inhibits Cells Adhesion Followed By Anoikis in Endothelial Cells - A Comparative Analysis with Cilengitide
Journal Title: Global Journal of Cancer Therapy - Year 2016, Vol 2, Issue 1
Abstract
Background: Despite the crucial role of integrin receptors in cancer pathogenesis and massive efforts towards establishing clinically relevant drugs, to the present no effective integrin antagonist for the treatment of malignant diseases has been introduced into the clinic. Context and purpose of the study: The purpose of the study was to examine the cellular effects and molecular mechanisms of a novel anti-integrin compound designated AV-398/38 and to compare it with cilengitide, one of the most advanced and best characterized αVβ3/αVβ5 integrin antagonists. AV-398/38 is a small molecule integrin antagonist that is currently in an early phase of pre-clinical evaluation. It was identified by virtual screening of chemical databases with the aim to detect novel integrin αVβ3 antagonist-like candidates. Based on preliminary in vitro data, the compound was recognized as a potential anti-neoplastic drug candidate, displaying high specificity and binding affinity in the nanomolar range towards the αVβ3 receptor, as well as showing potentially favorable drug-like properties. Results: Our studies revealed that its anti-neoplastic properties are most likely mediated by inhibition of integrin-mediated cell attachment to the extracellular matrix resulting in anoikis in a TP53 independent manner. Additionally, we observed inhibition of integrin-linked pathways involved in cell proliferation, survival and migration such as FAK, Akt, and MAPK as well as direct inhibitory effects on cell migration. We compared the effects of the compound with cilengitide, which is one of the best-characterized αVβ3 antagonists available. Main findings: The main finding was the observation, that AV-398/38 is capable of inducing cell death via induction of anoikis in a TP53 independent manner. Conclusions: Integrin αVβ3/αVβ5 inhibition leads to apoptotic cell death most likely triggered by a loss of adherence. Brief summary and potential implications: Our data indicate that compound AV-398/38 or structurally similar molecules may be promising candidates for preclinical development.
Authors and Affiliations
Christenheit Agnieszka, Heffeter Petra, Selzer Edgar
Keywords
Related Articles
- EP ID EP352847
- DOI 10.17352/2581-5407.000008
- Views 86
- Downloads 0
The Promise of Disease Management in Greece
Background: Disease Management (DM) is an approach to health care that coordinates resources across the entire health care delivery system and throughout the course of a disease. Objectives: The purpose of the present s...
Primary Spindle Cell Rhabdomyosarcoma of Prostate: A Case Report with Review of Literature
Primary spindle cell rhabdomyosarcoma of the prostate is an uncommon variant of embryonal rhabdomyosarcoma seen in pediatric age group mostly during infancy and childhood. Rhabdomyosarcoma (RMS) arising from prostate pre...
The Role of Decavanadate in Anti-Tumour Activity
Decavanadate compounds were described to be involved in a variety of biological activities and responses such as anti-virus, anti-bacterial and anticancer. While the mechanisms of action of the anti-viral and anti-bacter...
Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells
Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in se...
Bortezomib in Anti-Cancer Activity: A Potential Drug
26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhe...